Development and validation of an in vitroein vivo correlation (IVIVC) model for propranolol hydrochloride extended-release matrix formulations

Chinhwa Cheng, Pao Chu Wu, Hsin Ya Lee, Kuang Yang Hsu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The objective of this study was to develop an in vitroein vivo correlation (IVIVC) model for hydrophilic matrix extended-release (ER) propranolol dosage formulations. The in vitro release characteristics of the drug were determined using USP apparatus I at 100 rpm, in a medium of varying pH (from pH 1.2 to pH 6.8). In vivo plasma concentrations and pharmacokinetic parameters in male beagle dogs were obtained after administering oral, ER formulations and immediate-release (IR) commercial products. The similarity factor f2 was used to compare the dissolution data. The IVIVC model was developed using pooled fraction dissolved and fraction absorbed of propranolol ER formulations, ER-F and ER-S, with different release rates. An additional formulation ER-V, with a different release rate of propranolol, was prepared for evaluating the external predictability. The results showed that the percentage prediction error (%PE) values of Cmax and AUC0-∞ were 0.86% and 5.95%, respectively, for the external validation study. The observed low prediction errors for Cmax and AUC0eN demonstrated that the propranolol IVIVC model was valid.

Original languageEnglish
Pages (from-to)257-263
Number of pages7
JournalJournal of Food and Drug Analysis
Volume22
Issue number2
DOIs
Publication statusPublished - Jun 1 2014

Fingerprint

propranolol
Propranolol
prediction
Validation Studies
Beagle
pharmacokinetics
mouth
Pharmacokinetics
Dogs
drugs
dogs
dosage

Keywords

  • Extended-release dosage
  • IVIVC
  • Propranolol

ASJC Scopus subject areas

  • Food Science
  • Pharmacology

Cite this

Development and validation of an in vitroein vivo correlation (IVIVC) model for propranolol hydrochloride extended-release matrix formulations. / Cheng, Chinhwa; Wu, Pao Chu; Lee, Hsin Ya; Hsu, Kuang Yang.

In: Journal of Food and Drug Analysis, Vol. 22, No. 2, 01.06.2014, p. 257-263.

Research output: Contribution to journalArticle

@article{e52fd12b8d0e461ebcba308d3de1a555,
title = "Development and validation of an in vitroein vivo correlation (IVIVC) model for propranolol hydrochloride extended-release matrix formulations",
abstract = "The objective of this study was to develop an in vitroein vivo correlation (IVIVC) model for hydrophilic matrix extended-release (ER) propranolol dosage formulations. The in vitro release characteristics of the drug were determined using USP apparatus I at 100 rpm, in a medium of varying pH (from pH 1.2 to pH 6.8). In vivo plasma concentrations and pharmacokinetic parameters in male beagle dogs were obtained after administering oral, ER formulations and immediate-release (IR) commercial products. The similarity factor f2 was used to compare the dissolution data. The IVIVC model was developed using pooled fraction dissolved and fraction absorbed of propranolol ER formulations, ER-F and ER-S, with different release rates. An additional formulation ER-V, with a different release rate of propranolol, was prepared for evaluating the external predictability. The results showed that the percentage prediction error ({\%}PE) values of Cmax and AUC0-∞ were 0.86{\%} and 5.95{\%}, respectively, for the external validation study. The observed low prediction errors for Cmax and AUC0eN demonstrated that the propranolol IVIVC model was valid.",
keywords = "Extended-release dosage, IVIVC, Propranolol",
author = "Chinhwa Cheng and Wu, {Pao Chu} and Lee, {Hsin Ya} and Hsu, {Kuang Yang}",
year = "2014",
month = "6",
day = "1",
doi = "10.1016/j.jfda.2013.09.016",
language = "English",
volume = "22",
pages = "257--263",
journal = "Journal of Food and Drug Analysis",
issn = "1021-9498",
publisher = "Elsevier Taiwan LLC",
number = "2",

}

TY - JOUR

T1 - Development and validation of an in vitroein vivo correlation (IVIVC) model for propranolol hydrochloride extended-release matrix formulations

AU - Cheng, Chinhwa

AU - Wu, Pao Chu

AU - Lee, Hsin Ya

AU - Hsu, Kuang Yang

PY - 2014/6/1

Y1 - 2014/6/1

N2 - The objective of this study was to develop an in vitroein vivo correlation (IVIVC) model for hydrophilic matrix extended-release (ER) propranolol dosage formulations. The in vitro release characteristics of the drug were determined using USP apparatus I at 100 rpm, in a medium of varying pH (from pH 1.2 to pH 6.8). In vivo plasma concentrations and pharmacokinetic parameters in male beagle dogs were obtained after administering oral, ER formulations and immediate-release (IR) commercial products. The similarity factor f2 was used to compare the dissolution data. The IVIVC model was developed using pooled fraction dissolved and fraction absorbed of propranolol ER formulations, ER-F and ER-S, with different release rates. An additional formulation ER-V, with a different release rate of propranolol, was prepared for evaluating the external predictability. The results showed that the percentage prediction error (%PE) values of Cmax and AUC0-∞ were 0.86% and 5.95%, respectively, for the external validation study. The observed low prediction errors for Cmax and AUC0eN demonstrated that the propranolol IVIVC model was valid.

AB - The objective of this study was to develop an in vitroein vivo correlation (IVIVC) model for hydrophilic matrix extended-release (ER) propranolol dosage formulations. The in vitro release characteristics of the drug were determined using USP apparatus I at 100 rpm, in a medium of varying pH (from pH 1.2 to pH 6.8). In vivo plasma concentrations and pharmacokinetic parameters in male beagle dogs were obtained after administering oral, ER formulations and immediate-release (IR) commercial products. The similarity factor f2 was used to compare the dissolution data. The IVIVC model was developed using pooled fraction dissolved and fraction absorbed of propranolol ER formulations, ER-F and ER-S, with different release rates. An additional formulation ER-V, with a different release rate of propranolol, was prepared for evaluating the external predictability. The results showed that the percentage prediction error (%PE) values of Cmax and AUC0-∞ were 0.86% and 5.95%, respectively, for the external validation study. The observed low prediction errors for Cmax and AUC0eN demonstrated that the propranolol IVIVC model was valid.

KW - Extended-release dosage

KW - IVIVC

KW - Propranolol

UR - http://www.scopus.com/inward/record.url?scp=84914669549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914669549&partnerID=8YFLogxK

U2 - 10.1016/j.jfda.2013.09.016

DO - 10.1016/j.jfda.2013.09.016

M3 - Article

VL - 22

SP - 257

EP - 263

JO - Journal of Food and Drug Analysis

JF - Journal of Food and Drug Analysis

SN - 1021-9498

IS - 2

ER -